Skip to main content
SpringerLink
Log in

Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Cathepsin D is a lysosomal acid proteinase which is involved in the malignant progression of breast cancer and other gynecological tumors. Clinical investigations have shown that in breast cancer patients cathepsin D overexpression was significantly correlated with a shorter free-time disease and overall survival, whereas in patients with ovarian or endometrial cancer this phenomenon was associated with tumor aggressiveness and a degree of chemoresistance to various antitumor drugs such as anthracyclines, cis-platinum and vinca alkaloids. Therefore, a lot of research has been undertaken to evaluate the role and the prognostic value of cathepsin D also in other solid neoplasms. However, conflicting results have been generated from these studies. The discrepancies in these results may, in part, be explained with the different methodological approaches used in order to determine the levels of expression of the enzyme in tumor tissues and body fluids. Further investigations using well-standardized techniques may better define the clinical significance of cathepsin D expression in solid tumors. Nevertheless, evidence emerging from these studies indicates that this proteinase seems to facilitate early phases of tumor progression such as cell proliferation and local dissemination. These findings support the concept that cathepsin D may be a useful marker for identifying patients with highly malignant tumor phenotypes who may need more aggressive clinical treatment; this enzyme may also be considered as a potential target for a novel therapeutic approach in the treatment of solid neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barrett AJ. Cathepsin D and other carboxyl proteinases. In Barrett AJ (ed): Proteinases in Mammalian Cells and Tissues. Elsevier/North Holland Biomedical Press 1977; 209–29.

  2. Authier F, Mort JS, Bell AW et al. Proteolysis of glucagon within hepatic endosomes by membrane-associated cathepsin B and cathepsin D. J Biol Chem 1995; 270: 15798–807.

    PubMed  CAS  Google Scholar 

  3. Dunn AD, Crutchfield HE, Dunn JT. Proteolytic processing of thyreoglobulin by extracts of thyroid lysosomes. Endocrinology 1991; 128(6): 3073–80.

    PubMed  CAS  Google Scholar 

  4. Metaye T, Kraimpis JL, Goujon JM et al. Expression localization and thyrotropin regulation of cathepsin D in human thyroid tissues. Clin Endocrinol Metab 1997; 82 (10): 3383–8.

    CAS  Google Scholar 

  5. Ollinger K. Inhibition of cathepsin D prevents free-radical induced apoptosis in rat cardiomyocites. Arch Biochem Biophys 2000; 373 (2): 346–51.

    PubMed  CAS  Google Scholar 

  6. Roberg K, Kagedal K, Ollinger K. Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblast. Am J Pathol 2002; 161 (1): 89–96.

    PubMed  CAS  Google Scholar 

  7. Takuma K, Kiriu M, Mori K et al. Roles of cathepsins in riperfusion-induced apoptosis in cultured astrocytes. Neuochem Int 2003; 42 (2): 153–9.

    CAS  Google Scholar 

  8. Bidere N, Lorenzo HK, Carmona S et al. Cathepsin D triggers Bax activation, resulting in a selective apoptosis-inducing factor in T-lymphocytes entering in the early compartment phase of apoptosis. J Biol Chem 2003; 278 (33): 3140–4.

    Google Scholar 

  9. Shibata M, Kanamori S, Isahara K et al. Participation of cathepsin B and D in apoptosis of PC12 cells following serum deprivation. Biochem Biophys Res Comm 1998; 51: 199–203.

    Google Scholar 

  10. Deiss LP, Galika H, Berissi H et al. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J 1996; 15 (15): 3861–70.

    PubMed  CAS  Google Scholar 

  11. Alfonso S, Romagnano L, Barbiaz B. Expression of cathepsin proteinases by mouse trophoblast in vivo and in vitro. Dev Dyn 1999; 216 (4-5): 374–84.

    Google Scholar 

  12. Moulton BC, Khan SA. Progestin and estrogen control of cathepsin D expression and processing in rat uterine luminal epithelium and stroma-myometrium. Proc Soc Exp Biol Med 1992; 201: 98–105.

    PubMed  CAS  Google Scholar 

  13. Van der Stappen JWJ, Williams AC, Maciewcz RA, Paraskeva C. Activation of cathepsin B by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996; 67: 547–54.

    PubMed  CAS  Google Scholar 

  14. Vetvicka V, Fusek M. Activation of peripheral blood neutrophils and lymphocytes by human procathepsin D and insulin-like growth factor II. Cell Immunol 1994; 156: 332–41.

    PubMed  CAS  Google Scholar 

  15. Vetvicka V, Vetvickova J, Fusek M. Participation of the propeptide on procathepsin D activation of human peripheral lymphocytes. Arch Biochem Biophys 1995; 322(1): 295–98.

    CAS  Google Scholar 

  16. Simon DI, Ezratty AM, Loscalzo J. The fibrin(ogen)olytic properties of cathepsin D. Biochemistry 1994; 33: 6555–63.

    PubMed  CAS  Google Scholar 

  17. Satfig P, Hetman M, Schmahl W et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995; 14 (15): 3599–3608.

    Google Scholar 

  18. Redecker B, Heckendorf B, Grosh HW et al. Molecular organization of the human cathepsin D gene. DNA Cell Biol 1991; 10: 423–31.

    Article  PubMed  CAS  Google Scholar 

  19. Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis: A protease and a ligand. APMIS 1999; 107: 86–95.

    Article  PubMed  CAS  Google Scholar 

  20. Whitaker JN, Rhodes RH. The distribution of cathepsin D in rat tissue determined by immunocytochemistry. Am J Anat 1983; 166: 417–28.

    PubMed  CAS  Google Scholar 

  21. Decker RS, Decker ML, Poole R. The distribution of lysosomal cathepsin D in cardiac myocytes. J Histochem Cytochem 1980; 28: 231–7.

    PubMed  CAS  Google Scholar 

  22. Reid WA, Valler MJ, Kay J. Immunolocalization of cathepsin D in normal and neoplastic tissues. J Clin Pathol 1986; 39: 1323–30.

    PubMed  CAS  Google Scholar 

  23. Robson DK, Ironside JW, Reid WA, Bougue PR. Immunolocalization of cathepsin D in the human central nervous system and central nervous system neoplasms. Neuropathol Appl Neurobiol 1990; 16: 39–44.

    PubMed  CAS  Google Scholar 

  24. Parham D, Whitaker JN, Costan W, Berard CW. Cellular distribution of cathepsin D in childhood tumors. Arch Pathol Lab Med 1985; 109: 250–5.

    PubMed  CAS  Google Scholar 

  25. Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases (Review). Anticancer Res 1992; 12: 235–40.

    PubMed  CAS  Google Scholar 

  26. Rochefort H, Garcia M, Glondu M et al. Cathepsin D in breast cancer: Mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000; 291: 157–70

    PubMed  CAS  Google Scholar 

  27. Rochefort H, Chalbos D, Cunat S et al. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Ster Biochem Molec Biol 2001; 76: 119–24.

    CAS  Google Scholar 

  28. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulate cell growth and secretion of procathepsin D and a 120 kilodalton protein in human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1995; 75: 1497–502.

    Google Scholar 

  29. Touitou I, Cavailles V, Garcia M et al. Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Molec Cell Endocrinol 1989; 66: 231–8.

    PubMed  CAS  Google Scholar 

  30. Maudelonde T, Martinez P, Brouillet JP et al. Cathepsin D in endometrium: Induction by progesteron and potential value as tumor marker. Endocrinol Metab 1990; 70: 115–21.

    CAS  Google Scholar 

  31. Lah T, Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 1998; 379: 125–30.

    PubMed  CAS  Google Scholar 

  32. Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Hemostasis 1997; 78: 285–96.

    CAS  Google Scholar 

  33. Cox G, O'Byrne KJ. Matrix Metalloproteinases and cancer. Anticancer Res 2001; 21: 4207–20.

    PubMed  CAS  Google Scholar 

  34. Glondu M, Coopman P, Laurent-Matha V et al. A mutated cathepsin D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene 2001; 20(47): 6920–9.

    Google Scholar 

  35. Berchem G, Glondu M, Gleizes M et al. Cathepsin D affects multiple tumor progression steps in vivo: Proliferation, angiogenesis and apoptosis. Oncogene 2002; 21(38): 5951–5.

    PubMed  CAS  Google Scholar 

  36. Liaudet E, Derocq D, Rochefort H, Garcia M. Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth factors. Cell Growth Differ 1995; 66: 1045–52.

    Google Scholar 

  37. Ferrandina G, Scambia G, Bardelli F et al. Relationship betweeen cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. B J Cancer 1997; 76: 661–6.

    CAS  Google Scholar 

  38. Foekens JA, Look MP, Bolt-de Vries J et al. Cathepsin D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300–7.

    PubMed  CAS  Google Scholar 

  39. Roger S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptors in male breast carcinoma. Human Pathol 1993; 24 (2): 148–51.

    Google Scholar 

  40. Mejer-vanGolder ME, Look MP, Boldt-de Vries J et al. Clinical relevance of biological factors in male breast cancer. Breast Cancer Res Treat 2001; 68 (5): 249–60.

    Google Scholar 

  41. Henzen-Logmans S, Fieret EJH, Berns EMJJ et al. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal growth factor receptor and cathepsin D. Int J Cancer 1994; 57: 468–72.

    PubMed  CAS  Google Scholar 

  42. Ruppert C, Ehrenforth S, Scharrer I, Halberstadt E. Protease levels in breast ovarian and other gynecological tumor tissue. Prognostic importance in breast cancer. Cancer Detect Prev 1997; 21 (5): 452–9.

    PubMed  CAS  Google Scholar 

  43. Scambia G, Panici PB, Ferrandina et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994; 30A (7): 935–40.

    PubMed  CAS  Google Scholar 

  44. Athanassiadou P, Sakellariou V, Petrakakou E et al. Cathepsin D immunoreactivity in ovarian cancer: Correlation with prognostic factors. Pathol Oncol Res 1998; 4 (2): 103–7.

    PubMed  CAS  Google Scholar 

  45. Baekelandt M, Holm R, Trope CG et al. The significance of metastasis-related factors cathepsin D and nm23 in advanced ovarian cancer. Ann Oncol 1999; 10 (11): 1335–41.

    PubMed  CAS  Google Scholar 

  46. Ferrandina G, Scambia G, Fagotti A et al. Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: Lack of association with clinical outcome. Br J Cancer 1998; 78 (12): 1645–52.

    PubMed  CAS  Google Scholar 

  47. Nazeer T, Malfetano JH, Rosano TG, Ross JS. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Am J Clin Pathol 1992; 97 (6): 764–9.

    PubMed  CAS  Google Scholar 

  48. Nazeer T, Church K, Amato C et al. Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: Predictor of tumor aggressiveness. Mod Pathol 1994; 7 (4): 469–74.

    PubMed  CAS  Google Scholar 

  49. Nielsen AL, Nyholm HCJ. Endometrial adenocarcinoma of the endometrioid subtype with squamous differentiation: An immunohistochemical study of MIB-1 (ki-67 paraffin), cathepsin D and C-erbB-2 protein (p185). Int J Gynecol Pathol 1995; 14: 230–4.

    Article  PubMed  CAS  Google Scholar 

  50. Scambia G, Benedetti Panici P, Ferrandina F et al. Significance of cathepsin D expression in uterine tumors. Eur J Cancer 1995; 31A (9): 1449–54.

    PubMed  CAS  Google Scholar 

  51. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996; 78 (3): 433–40.

    PubMed  CAS  Google Scholar 

  52. Falcon O, Chirino R, Leon L et al. Low levels of cathepsin D are associated with poor prognosis in endometrial cancer. Br J Cancer 1999; 79 (3-4): 570–6.

    PubMed  CAS  Google Scholar 

  53. Saygili U, Koyuncuoglu M, Altunyurt S et al. May cathepsin D immunoreactivity be used as prognostic factor in endometrial carcinoma? A comparative immunohistochemical study. Gynecol Oncol 2001; 83 (1): 20–4.

    PubMed  CAS  Google Scholar 

  54. Mylonas I, Makovitzky J, Richter DU et al. Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: An immunohistochemical analysis. Acta Histochem 2003; 105 (3): 245–52.

    PubMed  Google Scholar 

  55. Bazzett LS, Watkins CS, Gercel-Taylor C, Taylor DP. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gynecol Oncol 1999; 74: 181–87.

    PubMed  CAS  Google Scholar 

  56. Salvesen GS, Dixit VM. Caspases: Intracellular signalling by proteolysis. Cell 1997; 91: 443–6.

    PubMed  CAS  Google Scholar 

  57. Isahara K, Ohsawa Y, Kanamori S et al. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neurosci 1999; 91 (1): 233–49.

    CAS  Google Scholar 

  58. Kohnken R, Ladror US, Wang GT et al. Cathepsin D from Alzheimer's diseased and normal brains. Exp Neurol 1995; 133: 105–12.

    PubMed  CAS  Google Scholar 

  59. Cataldo AM, Barnett JL, Berman SA et al. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system. Neuron 1995; 14: 671–80.

    PubMed  CAS  Google Scholar 

  60. Newbould MJ, Kelsey AM, Arango GJ et al. The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations. Histopathology 1995; 26 (2): 137–43.

    PubMed  CAS  Google Scholar 

  61. Warich M, von Bossanyi P, Dietzmann K. Expression of cathepsin D in human astrocytic neoplasias. Gen Diagn Pathol 1995; 141 (2): 193–6.

    Google Scholar 

  62. Castilla EA, Prayson RA, Abramovich CM, Cohen ML. Immunohistochemical expression of cathepsin D in meningiomas. Am J Pathol 2003; 19 (1): 123–8.

    Google Scholar 

  63. Sivaparvathi M, Sawaya R, Chintala SK et al. Expression of cathepsin D during progression of human gliomas. Neurosci Lett 1996; 208: 171–4.

    PubMed  CAS  Google Scholar 

  64. Tew DS. Adhesive and invasive features in gliomas. Pathol Res Prat 2000; 196 (10): 701–11.

    Google Scholar 

  65. Castino R, Pace D, Demoz M et al. Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas. Int J Cancer 2002; 97 (6): 775–9.

    PubMed  CAS  Google Scholar 

  66. Tumminello FM, Bernacki RJ, Gebbia N, Leto G. Pepstatins, aspartic proteinase inhibitors having potential therapeutic applications. Med Res Rev 1993; 13: 199–208.

    PubMed  CAS  Google Scholar 

  67. Marsigliante S, Biscozzo L, Resta L et al. Immunohistochemical and immunoradiometric evaluation of total cathepsin D in human larynx. Eur J Cancer 1994; 30B: 51–5.

    CAS  Google Scholar 

  68. Vigneswaran N, Muller S, DeRose P, Cohen C. Cathepsin D and tumor associated antigen DF3 in salivary gland neoplasia: Differential diagnostic and prognostic applications. Path Res Pract 1994; 190: 1174–84

    PubMed  CAS  Google Scholar 

  69. Kos J, Smid A, Krasovec M et al. Lysosomal proteases cathepsin D, B, H and L and their inhibitors Stefin A and B in head and neck cancer. Biol Chem Hoppe-Seyler 1995; 376: 401–5.

    PubMed  CAS  Google Scholar 

  70. Zeillinger H, Eder S, Schneeberger CH et al. Cathepsin D and PAI-1 expression in human head and neck cancer. Anticancer Res 1996; 16: 449–54.

    PubMed  CAS  Google Scholar 

  71. Strojan P, Budhina M, Smid L et al. Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Lett 1998; 130: 49–56.

    PubMed  CAS  Google Scholar 

  72. Goussa A, Ioachim E, Peschos D et al. Immunohistochemical expression of cathepsin D in laryngeal epithelial lesions: Correlation with CD44 expression, p53 and Rb status and proliferation associated indices. Anticancer Res 1999; 19 (B): 3055–60.

    Google Scholar 

  73. Vigneswaran N, Zhao W, Dassanayake A et al. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Human Pathol 2000; 31 (8): 931–7.

    CAS  Google Scholar 

  74. Kawasaki G, Kato Y, Mizuno A. Cathepsin D expression in oral squamous cell carcinoma: Relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93 (4): 446–54.

    Article  PubMed  Google Scholar 

  75. Gandour-Edward ER, Trock B, Donald PJ. Predictive value of cathepsin D for cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 1999; 21 (8): 718–22.

    Google Scholar 

  76. Osmak M, Niksic D, Brozovic A et al. Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis. Anticancer Res 1999; 19: 3193–8.

    PubMed  CAS  Google Scholar 

  77. Leto G, Tumminello FM, Gebbia N et al. Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: Clinical implications. Int J Biol Markers 2001; 16 (4): 245–9.

    PubMed  CAS  Google Scholar 

  78. Resnick MJM, Uhlman D, Niehans G et al. Cervical lymph node status and survival in laryngeal carcinoma: Prognostic factors. Ann Otol Rhinol Laryngol 1995; 104: 685–94.

    PubMed  CAS  Google Scholar 

  79. Seiwerth S, Stambuk N, Konjevoda P et al. Immunohistochemical analysis and prognostic value of cathepsin D determination in laryngeal squamous cell carcinoma. J Chem Inf Comput Sci 2000; 40 (3): 545–9.

    PubMed  CAS  Google Scholar 

  80. Lazaris AC, Lendari I, Kavantzas N et al. Correlation of tumor markers p53, bcl 2 and cathepsin D with clinicopathological features and disease free survival in laryngeal suamous cell carcinoma. Pathol Int 2000; 50: 717–24.

    PubMed  CAS  Google Scholar 

  81. Maurizi M, Almadori G, Cadoni G et al. Cathepsin D concentrations in primay laryngeal cancer: Correlation with clinico-pathological parameters, EGFR status and prognosis. Int J Cancer 1996; 69 (2): 105–9.

    PubMed  CAS  Google Scholar 

  82. Budihna M, Strojan P, Smid L et al. Prognostic value of cathepsin B, H, L, D and their endogenous inhibitors Stefin A and B in head and neck carcinoma. Biol Chem Hoppe-Seyler 1996; 377: 385–90.

    PubMed  CAS  Google Scholar 

  83. Metaye T, Millet C, Kraimps JL et al. Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 1993; 72 (6): 1991–6.

    PubMed  CAS  Google Scholar 

  84. Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992; 72: 667–97.

    PubMed  CAS  Google Scholar 

  85. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocrinol Rev 1994; 13: 596–611.

    Google Scholar 

  86. Sinadinovic J, Cvejic D, Savin S et al. Enhanced acid protease activity of lysosomes from papillary thyroid carcinoma. Cancer 1989; 63: 1179–82.

    PubMed  CAS  Google Scholar 

  87. Kraimps JL, Metaye T, Millett C et al. Cathepsin D in normal and neoplastic thyroid tissues. Surgery 1995; 118 (6): 1036–40.

    PubMed  CAS  Google Scholar 

  88. Ruhoy SM, Clarke MR. Cathepsin B and D expression in follicular adenomas and carcinomas of the thyroid gland. Endocrin Pathol 1997; 8 (1): 49–57.

    Google Scholar 

  89. Holm R, Hoie J, Kaalhus O et al. Immunohistochemical detection of nm23/NDP kinase and cathepsin D in medullary carcinoma of the thyroid gland. Virchows Arch 1995; 427 (3): 289–94.

    PubMed  CAS  Google Scholar 

  90. Ledakis P, Tester WT, Rosenberg N et al. Cathepsin D, B and L in malignant human lung tissue. Clin Cancer Res 1996; 2 (3): 561–8.

    PubMed  CAS  Google Scholar 

  91. Fontanini G, Bigini D, Vignati S et al. Immunostaining of cathepsin D in non-small cell lung cancer: Correlation with morphological and biological parameters. Int J Oncol 1994; 4: 169–73.

    Google Scholar 

  92. Sloman A, Damico F, Yousem SA. Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study. Arch Pathol Lab Med 1996; 120 (5): 465–72.

    PubMed  CAS  Google Scholar 

  93. Higashiyama M, Doi O, Kodama K et al. Influence of cathepsin D expression in lung adenocarcinoma on prognosis: Possible importance of its expression in tumor cells and stromal cells and its intracellular polarization in tumor cells. J Surg Oncol 1997; 65 (1): 10–9.

    PubMed  CAS  Google Scholar 

  94. Wozniack A, Drewa T, Rozwodowska M et al. Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma. Neoplasma 2002; 49 (1): 10–5.

    Google Scholar 

  95. Saku T, Sakai H, Tsuda T et al. Cathepsin D and E in normal metaplastic, dysplastic and carcinomatous gastric tissue: An immunohistochemical study. Gut 1990; 31: 1250–5.

    PubMed  CAS  Google Scholar 

  96. Matsuo K, Kobayashi I, Tsukuba T et al. Immunohistochemical localization of cathepsin D and E in human gastric tissue. Hum Pathol 1996; 27 (2): 184–90.

    PubMed  CAS  Google Scholar 

  97. Kantsaliev AL, Kozyreva EA, Kushlinskii NE et al. Cathepsin D activity in gastric cancer. Vopr Onkol 1994; 40 (1-3): 40–6.

    PubMed  CAS  Google Scholar 

  98. Kashida H, Kawamata H, Ichikawa K et al. Intracytoplasmic localization of cathepsin D reflects the invasive potential of gastric carcinoma. J Gastroenterol 2001; 36 (12): 809–15.

    PubMed  CAS  Google Scholar 

  99. Allgayer H, Babic R, Grutzner KU et al. Tumor associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease pattern. Clin Exp Med 1998; 16(1): 62–73.

    CAS  Google Scholar 

  100. Russo A, Bazan V, Migliavacca M et al. Prognostic significance of DNA ploidy, S-phase fraction and tissue levels of aspartic, cysteine and serine proteases in operable gastric carcinoma. Clin Cancer Res 2001; 6: 178–84.

    Google Scholar 

  101. Goishi H, Tanaka S, Haruma K et al. Predictive value of cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer. Oncol Rep 2000; 7 (4): 713–8.

    PubMed  CAS  Google Scholar 

  102. Ikeguchi M, Fukuda K, Oka S-I et al. Micro-lymph node metastasis and its correlation with cathepsin D expression in early gastric cancer. J Surg Oncol 2001; 77: 188–94.

    PubMed  CAS  Google Scholar 

  103. Ikeguchi M, Fukuda K, Oka S et al. Clinicopathological significance of cathepsin D expression in gastric adenocarcinomas. Oncology 2001; 61: 71–8.

    PubMed  CAS  Google Scholar 

  104. Garcia I, Vizoso F, Suarez C et al. Relationship of tumoral hyaluronic acid and cathepsin D contents with histological type of gastric carcinoma. Int J Biol Markers 2000; 15 (3): 215–8.

    PubMed  CAS  Google Scholar 

  105. Leto G, Tumminello FM, Russo A et al. Cathepsin D activity levels in colorectal cancer: Correlation with Cathepsin B and L and other biological and clinical parameters. Int J Oncol 1995; 5: 509–515.

    Google Scholar 

  106. Adenis A, Huet G, Zerimech F et al. Cathepsin B, L and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Cancer Lett 1995; 96: 267–75.

    PubMed  CAS  Google Scholar 

  107. Tumminello FM, Gebbia N, Pizzolanti G et al. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological and clinical parameters. Oncology 1995; 52: 237–42.

    PubMed  CAS  Google Scholar 

  108. Theodoropoulos GE, Panoussopoulos D, Lazaris AC, Golematis BC. Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma. J Surg Oncol 1997; 65 (4): 242–8.

    PubMed  CAS  Google Scholar 

  109. Kanber Y, Demirbag NR, Sam AD, Aydin N. Cathepsin D expression in colorectal adenocarcinomas and adenomas. Int J Biol Markers 2002; 17 (3): 165–8.

    PubMed  CAS  Google Scholar 

  110. Arao J, Fukui H, Ono Y et al. Immunohistochemical localization of cathepsin D in colorectal tumors. Dis Colon Rectum 2000; 43: 396–401.

    PubMed  CAS  Google Scholar 

  111. Oh-e H, Tanaka S, Kitadai Y et al. Cathepsin D expression as possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur J Cancer 2001; 37 (2): 180–8.

    PubMed  CAS  Google Scholar 

  112. GalandiuK S, Miseljic S, Yang A-R et al. Expression of hormone receptors, cathepsin D and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg 1993; 128: 637–4.

    PubMed  CAS  Google Scholar 

  113. Huet G, Zerimech F, Dieu MC et al. The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and plasminogen activator. Int J Cancer 1994; 57: 875–82.

    PubMed  CAS  Google Scholar 

  114. Stefanis D, Reffo P, Bonelli G et al. Increase in ceramide level alters the lysosomal targeting of cathepsin D prior to onset of apoptosis in HT-29 colon cancer cells. Biol Chem 2002; 383 (6): 989–99.

    PubMed  Google Scholar 

  115. Movsesyan VA, Yakovlev AG, Dabaghyan CA et al. Ceramide induced neuronal apoptosis through the caspase-9/caspase-3 pathway. Biochem Biophys Res Commun 2002; 299 (2): 201–7.

    PubMed  CAS  Google Scholar 

  116. Krishnamachary B, Berg-Dixon S, Kelly B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63 (5): 1138–43.

    PubMed  CAS  Google Scholar 

  117. Caruso ML, Valentini AM. Immunohistochemical p53 overexpression correlated to c-erbB and cathepsin D proteins in colorectal cancer. Anticancer Res 1996; 16: 3813–8.

    PubMed  CAS  Google Scholar 

  118. Isidoro C, Demoz M, De Stefanis D et al. Altered intracellular processing and enhanced secretion of procathepsin D in a highly deviated rat hepatoma. Int J Cancer 1995; 60: 61–4

    PubMed  CAS  Google Scholar 

  119. Isidoro C, Demoz M, Baccino FM, Bonelli G. High levels of proteolytic enzymes in the ascitic fluid and plasma of rats bearing Yoshida AH-130 hepatoma. Invas Metast 1995; 15: 116–24.

    CAS  Google Scholar 

  120. Maguchi S, Taniguchi N, Makita A. Elevated activity and increased mannose-6-phosphate in the carbohydrate moiety of cathepsin D from human hepatoma. Cancer Res 1988; 48: 362–7.

    PubMed  CAS  Google Scholar 

  121. Kyaw A, Aung T, Htut T et al. Lysosomal enzyme activities in normals and patients with chronic liver diseases. Clin Chim Acta 1983; 151 (3): 317–23

    Google Scholar 

  122. Zuhlsdorf M, Imort M, Hasilik A, von Figura K. Molecular forms of beta hexosaminidase and cathepsin D in serum and urine of healthy subjects and patients with elevated activity of lysosomal enzymes. Biochem J 1983; 213: 733–40.

    PubMed  CAS  Google Scholar 

  123. Brouillet JP, Hanslick B, Maudelonde MT et al. Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. Clin Biochem 1991; 24: 491–6.

    PubMed  CAS  Google Scholar 

  124. Leto G, Tumminello FM, Pizzolanti G et al. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. Eur J Clin Chem Clin Biochem 1996; 34: 555–60.

    PubMed  CAS  Google Scholar 

  125. Morioka M, Terayama H. Cathepsin D stimulates DNA-syntesis and mitosis in mouse liver in vivo. Exp Cell Res 1983; 151: 273–6.

    Google Scholar 

  126. Terayama H, Morioka M, Koij T. Mitogenic effects of certain cathepsins and calciferin on intact liver in vivo. Int J Biochem 1985; 17: 945–55.

    Google Scholar 

  127. Ito H, Miyazaki M, Nishimura F, Nakajima N. Secretion of extracellular matrix (fibronectin), growth factor (transforming growth factor β) and protease (cathepsin D) by hepatoma cells. Oncology 2000; 58: 261–70.

    PubMed  CAS  Google Scholar 

  128. Ryvnyak VV, Gudumak VS, Onya ES. Intracellular and extracellular cathepsin D activity in the liver during cirrhosis and involution. Bull Exp Biol Med Engl Trans 1990; 109 (2): 250–3.

    Google Scholar 

  129. Terayama H, Shimizu N, Fukuzumi R. Calciferin and cathepsin D-like acid protease in serum in acute and chronic liver injuries in rats and humans. Clin Chem 1989; 35 (11): 2202–06.

    PubMed  CAS  Google Scholar 

  130. Leto G, Tumminello FM, Pizzolanti G et al. Lysosomal cathepsin B and L and stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis. Potential clinical implications. Oncology 1997; 54: 79–8.

    Article  PubMed  CAS  Google Scholar 

  131. Theret N, Musso O, Turlin B et al. Increased extracellular matrix remodelling is associated with tumor progression in human hepatocellular carcinoma. Hepatol 2001; 34 (1): 82–8.

    CAS  Google Scholar 

  132. Huang XF, Wang CM, Dai XW et al. Expression of chromogranin A and cathepsin D in human primary hepatocellular carcinoma. World J Gastroenterol 2000; 6 (5): 693–8.

    PubMed  CAS  Google Scholar 

  133. Yamaguchi N, Kawai K. Acid protease secreted from human pancreatic carcinoma cell line HPC-YT into serum free, chemically defined medium. Cancer Res 1986; 46: 5353–9.

    PubMed  CAS  Google Scholar 

  134. Leto G, Tumminello FM, Pizzolanti G et al. Lysosomal aspartic and cysteine proteinases serum levels in pancreatic cancer or pancreatis. Pancreas 1997; 14: 22–7.

    PubMed  CAS  Google Scholar 

  135. Nakata B, Appert HE, Lei SZ et al. Immunohistochemical study on cathepsin B and cathepsin D in pancreatic cancer. Oncol Rep 1994; 1 (3): 543–6.

    Google Scholar 

  136. Niedergethmann M, Hildebrand R, Wolf G et al. Angiogenesis and cathepsins expression are prognostic factors in pancreatic carcinoma after curative resection. Int J Pancreatol 2000; 28 (1): 31–9.

    PubMed  CAS  Google Scholar 

  137. Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995; 80: 987–93.

    PubMed  CAS  Google Scholar 

  138. Nunn SE, Pechi DM, Cohen P. Acid-activated insulin-like growth factor binding protein protease activity of Cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 1997; 171 (2): 196–204.

    PubMed  CAS  Google Scholar 

  139. Mordente JA, Choudhury MS, Tazaki H et al. Hydrolysis of androgen receptor by cathepsin D: its biological significance in human prostatic cancer. Br J Urol 1998; 82 (3): 4431–5.

    Google Scholar 

  140. Vetvicka V, Vetvickova J, Fusek M. Role of procathepsin D activation peptide in prostatic cancer growth. Prostate. 2000; 44 (1): 1–7.

    PubMed  CAS  Google Scholar 

  141. Vetvicka V, Vetvickova J, Hilgert I et al. Analysis of the interaction of procathepsin D activation peptide with breast cancer cells. Int J Cancer 1997; 73: 403–9.

    PubMed  CAS  Google Scholar 

  142. Konno S, Cherry JP, Mordente JA et al. Role of cathepsin D in prostatic cancer cell growth and its regulation by brefeldin A. World J Urol 2001; 19 (4): 234–9.

    PubMed  CAS  Google Scholar 

  143. Konno S, Mordente JA, Chen Y et al. Effects of brefeldin A on androgen receptor-mediated cellular responses in human prostatic carcinoma LNCaP cells. Mol Urol 1998; 2: 7–11.

    CAS  Google Scholar 

  144. Morikawa W, Yamamoto K, Ishikawa S et al.. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 2000; 275 (49): 38912–20.

    PubMed  CAS  Google Scholar 

  145. Cherry JP, Mordente JA, Chapman JR et al. Analysis of cathepsin D forms and their clinical implications in human prostatic cancer. J Urol 1998; 160 (6 Pt 1): 2223–8.

    PubMed  CAS  Google Scholar 

  146. Yang Y, Chisholm GD, Habib FK. The distribution of PSA, cathepsin D and pS2 in BPH and cancer of the prostate. Prostate 1992; 21 (3): 201–8.

    PubMed  CAS  Google Scholar 

  147. Chambon M, Rebillard X, Rochefort H et al. Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumor. Prostate 1994; 24 (6): 320–5.

    PubMed  CAS  Google Scholar 

  148. Makar R, Mason A, Kittelson JM et al. Immunohistochemical anaysis of cathepsin D in prostate carcinoma. Mod Pathol 1994; 7 (7): 747–51.

    PubMed  CAS  Google Scholar 

  149. Maygarden SJ, Novotny DB, Moul JB et al. Evaluation of cathepsin D and epidermial growth factor receptor in prostatic carcinoma. Mod Pathol 1994; 7 (9): 930–6.

    PubMed  CAS  Google Scholar 

  150. Ross JS, Nazeer T, Figge HL et al. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA levels and DNA ploidy status. Am J Clin Pathol 1995; 104: 36–41.

    PubMed  CAS  Google Scholar 

  151. Moul JW, Maygarden SJ, Ware JL et al. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 1996; 155 (3): 982–5.

    PubMed  CAS  Google Scholar 

  152. Theodorescu D, Broder SR, Boyd JC et al. Cathepsin D and chromogranin A as predictor of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997; 80 (11): 2109–19.

    PubMed  CAS  Google Scholar 

  153. Hara I, Miyake H, Yamanaka K et al. Serum cathepsin D and its density in men with prostatic cancer as new predictor of disease progression. Oncol Rep 2002; 9 (6): 1379–83.

    PubMed  Google Scholar 

  154. Myake H, Hara I, Eto H. Prediction of the extent of prostatic cancer by the combined use of systematic biopsy and serum levels of cathepsin D. Int J Urol 2003; 10 (4): 196–200.

    Google Scholar 

  155. Ioachim E, Charchanti A, Stavropoulos N et al. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: An immunohistochemical study including correlation with extracellular matrix components, CD44, p53, Rb, C-erb-2 and the proliferation indices. Anticancer Res 2002; 22 (6A): 3383–8.

    PubMed  CAS  Google Scholar 

  156. Dickinson AJ, Fox SB, Newcomb PV et al. An immunohistochemical and prognostic evaluation of Cathepsin D expression in 105 bladder carcinomas. J Urol 1995; 154: 237–41.

    PubMed  CAS  Google Scholar 

  157. Iizumi T, Iiyama T, Tanaka W et al. Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder. Urol Int 1997; 59 (2): 81–7.

    Article  PubMed  CAS  Google Scholar 

  158. Lipponen PK. Expression of cathepsin D in transitional cell bladder tumors. J Pathol 1996; 178(1): 59–4.

    PubMed  CAS  Google Scholar 

  159. Ozer E, Mungan MU, Tuna B et al. Prognostic significance and angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high grade stage T1 primary bladder. Urology 1999; 54 (1): 50–5.

    PubMed  CAS  Google Scholar 

  160. Salman T, el-Ahmady O, el Shafee M et al. The clinical value of cathepsin D and TNF-α in bladder cancer patients. Anticancer Res 1997; 17 (4B): 3087–90.

    PubMed  CAS  Google Scholar 

  161. Carrascosa Lloret C, Cremades MA, Sanchez Sanchis M et al. Study of cathepsin D levels in invasive bladder cancer and its stroma. Correlation with tumor stage, histological grade, lymph node metastasis and survival. Actas Urol Esp 2002; 26 (5): 335–8.

    PubMed  CAS  Google Scholar 

  162. Ferrier CM, van Muijen GNP, Ruiter DJ. Proteases in cutaneous melanoma. Ann Med 1998; 30: 431–42.

    PubMed  CAS  Google Scholar 

  163. Fraki EJ, Hopsu-Havu VK. Proteolytic enzymes and plasminogen activator in melanoma. J Cutan Pathol 1979; 6: 195–200.

    PubMed  CAS  Google Scholar 

  164. Tsushima H, Sumi H, Ikeda R et al. Purification and characterization of a cathepsin-D like enzyme from human melanoma tissue and its action on fibrinogen. Eur Rev Med Pharmacol Sci 1989; 11: 451–61.

    Google Scholar 

  165. Garcia M, Salazar-Retana G, Richer G et al. Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res 1986; 46: 3734–8.

    PubMed  CAS  Google Scholar 

  166. Podhajcer O, Bover L, Bravo AI et al. Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 1995; 104: 340–4.

    PubMed  CAS  Google Scholar 

  167. Kageshita T, Yoshii A, Kimura T et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumors. Arch Dermatol Res 1995; 287: 266–72.

    PubMed  CAS  Google Scholar 

  168. Frohlich E, Schlagenhauff B, Mohrle M et al. Activity, expression and trascription rate of the cathepsin B, D, H and L in cutaneous melanoma. Cancer 2001; 91(5): 972–82.

    PubMed  CAS  Google Scholar 

  169. Bartenjev I, Rudolf Z, Stabuc B et al. Cathepsin D expression in early cutaneous malignant melanoma. Int J Dermatol 2000; 39 (8): 599–602.

    PubMed  CAS  Google Scholar 

  170. Otto FJ, Goldmann T, Biess B et al. Prognostic classification of malignant melanomas by combining clinical, histological and immunohistochemical parameters. Oncology 1999; 56 (3): 208–14.

    PubMed  CAS  Google Scholar 

  171. Goldmann T, Suter L, Ribbdert D, Otto F. The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predict metastasis. Pathol Res Pract 1999; 195 (3): 171–5.

    PubMed  CAS  Google Scholar 

  172. Westhoff U, Fox C, Otto FJ. Quantification of cathepsin D in plasma of patients with malignant melanoma. Anticancer Res 1998; 18 (5B): 3785–8.

    PubMed  CAS  Google Scholar 

  173. Kawada A, Hara K, Kominami E et al. Cathepsin B and D expression in squamous cell carcinoma. Br J Dermatol 1996; 1135: 905–10.

    Google Scholar 

  174. Goldmann T, Moorkamp A, Wiedorn KH et al. The prognostic value of the expression of collagenase IV, cathepsin D and metallothein in squamous cell carcinoma of the skin determined by immunohistochemistry. Arch Dermatol Res 2001; 293 (3): 115–20.

    PubMed  CAS  Google Scholar 

  175. Leto G, Pizzolanti G, Tumminello FM and Gebbia N. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. In Vivo 1994; 8: 231–6.

    PubMed  CAS  Google Scholar 

  176. Bessodes M, Antonakis K, Herscovici J. Inhibition of cathepsin D by tripeptides containing statine analogs. Biochem Pharmacol 1999; 58 (2): 329–33.

    PubMed  CAS  Google Scholar 

  177. Solovyeva NI, Balayevskaya TO, Dilakian EA et al. Proteolytic enzymes at various stage of oncogenic transformation of rat fibroblasts. I Aspartyl and cysteine proteinases. Int J Cancer 1995; 60: 495–500.

    PubMed  CAS  Google Scholar 

  178. Isidoro C, Demoz M, De Stefanis D et al. Synthesis, maturation and extracellular release of procathepsin D as influenced by cell proliferation or trasformation. Int J Cancer 1995; 63: 966–71.

    Google Scholar 

  179. Schwartz MK. Tissue cathepsins as tumor markers. Clin Chim Acta 1995; 237: 67–78.

    PubMed  CAS  Google Scholar 

  180. Joensuu H, Toikkanen S, Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer patients. Br J Cancer 1995; 71: 155–9.

    PubMed  CAS  Google Scholar 

  181. Zang Y, Beard RL, Chandraratna RA, Kang JX. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukaemia HL-60 cells. Cell Growth Differ 2001; 8 (5): 477–85.

    CAS  Google Scholar 

  182. Wu GS, Satfig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998; 16: 2177–83.

    PubMed  CAS  Google Scholar 

  183. Ikeguchi M, Sakatani T, Ueta T et al. Correlation between Cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma. J Clin Pathol 2002; 55 (2): 121–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Chemotherapy, Department of Oncology, Policlinico Universitario `P. Giaccone', Palermo, Italy

    Gaetano Leto, Francesca M. Tumminello, Marilena Crescimanno, Carla Flandina & Nicola Gebbia

Authors
  1. Gaetano Leto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca M. Tumminello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marilena Crescimanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carla Flandina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicola Gebbia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gaetano Leto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leto, G., Tumminello, F.M., Crescimanno, M. et al. Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications. Clin Exp Metastasis 21, 91–106 (2004). https://doi.org/10.1023/B:CLIN.0000024740.44602.b7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CLIN.0000024740.44602.b7

Search

Navigation